These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 39450798)

  • 1. [What do we know about craniopharyngioma? Updated review of the main advances and local experience.].
    Hernández MI; Ibeas C; Gómez M; Valenzuela S; Ivanovic-Zuvic D; Fernández JP
    Rev Med Chil; 2024 Feb; 152(2):211-224. PubMed ID: 39450798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Craniopharyngioma in Pediatrics and Adults.
    Piloni M; Gagliardi F; Bailo M; Losa M; Boari N; Spina A; Mortini P
    Adv Exp Med Biol; 2023; 1405():299-329. PubMed ID: 37452943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary Biological Insights and Clinical Management of Craniopharyngioma.
    Apps JR; Muller HL; Hankinson TC; Yock TI; Martinez-Barbera JP
    Endocr Rev; 2023 May; 44(3):518-538. PubMed ID: 36574377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas.
    Yoshimoto K; Hatae R; Suzuki SO; Hata N; Kuga D; Akagi Y; Amemiya T; Sangatsuda Y; Mukae N; Mizoguchi M; Iwaki T; Iihara K
    Neuropathology; 2018 Feb; 38(1):3-10. PubMed ID: 28840946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adamantinomatous craniopharyngioma: moving toward targeted therapies.
    Hengartner AC; Prince E; Vijmasi T; Hankinson TC
    Neurosurg Focus; 2020 Jan; 48(1):E7. PubMed ID: 31896087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy.
    Martinez-Gutierrez JC; D'Andrea MR; Cahill DP; Santagata S; Barker FG; Brastianos PK
    Neurosurg Focus; 2016 Dec; 41(6):E2. PubMed ID: 27903124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Craniopharyngioma-An update on metabolic and cognitive complications and new therapy.
    Erfurth EM
    J Intern Med; 2023 Sep; 294(3):269-280. PubMed ID: 37424210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Implication of BRAF V600E and CTNNB1 gene mutations in the pathological classification of craniopharyngioma].
    Xu SS; Wang LM; Zhao LH; He ZL; Gong LP; Lu DH; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2019 Sep; 48(9):682-687. PubMed ID: 31495087
    [No Abstract]   [Full Text] [Related]  

  • 9. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.
    Brastianos PK; Taylor-Weiner A; Manley PE; Jones RT; Dias-Santagata D; Thorner AR; Lawrence MS; Rodriguez FJ; Bernardo LA; Schubert L; Sunkavalli A; Shillingford N; Calicchio ML; Lidov HG; Taha H; Martinez-Lage M; Santi M; Storm PB; Lee JY; Palmer JN; Adappa ND; Scott RM; Dunn IF; Laws ER; Stewart C; Ligon KL; Hoang MP; Van Hummelen P; Hahn WC; Louis DN; Resnick AC; Kieran MW; Getz G; Santagata S
    Nat Genet; 2014 Feb; 46(2):161-5. PubMed ID: 24413733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do craniopharyngioma molecular signatures correlate with clinical characteristics?
    Omay SB; Chen YN; Almeida JP; Ruiz-Treviño AS; Boockvar JA; Stieg PE; Greenfield JP; Souweidane MM; Kacker A; Pisapia DJ; Anand VK; Schwartz TH
    J Neurosurg; 2018 May; 128(5):1473-1478. PubMed ID: 28707994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Craniopharyngiomas.
    Hamblin R; Tsermoulas G; Karavitaki N
    Presse Med; 2021 Dec; 50(4):104078. PubMed ID: 34688870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of novel CTNNB1 mutation in Craniopharyngioma by whole-genome sequencing.
    He J; Zeng Z; Wang Y; Deng J; Tang X; Liu F; Huang J; Chen H; Liang R; Zan X; Liu Z; Tong A; Guo G; Xu J; Zhu X; Zhou L; Peng Y
    Mol Cancer; 2021 Dec; 20(1):168. PubMed ID: 34922552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Craniopharyngioma: a roadmap for scientific translation.
    Gupta S; Bi WL; Giantini Larsen A; Al-Abdulmohsen S; Abedalthagafi M; Dunn IF
    Neurosurg Focus; 2018 Jun; 44(6):E12. PubMed ID: 29852761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapies in the medical management of craniopharyngioma.
    Iglesias P
    Pituitary; 2022 Jun; 25(3):383-392. PubMed ID: 35301645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy in BRAF mutated aggressive papillary craniopharyngioma: a case report and overview of the literature.
    Losa M; Mazza E; Pedone E; Nocera G; Liscia N; Reni M; Mortini P
    J Endocrinol Invest; 2024 Nov; 47(11):2835-2842. PubMed ID: 38696125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases.
    Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Suri V; Sarkar C; Jagdevan A; Sharma BS; Sharma MC
    J Neurooncol; 2017 Jul; 133(3):487-495. PubMed ID: 28500561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma.
    Larkin SJ; Preda V; Karavitaki N; Grossman A; Ansorge O
    Acta Neuropathol; 2014; 127(6):927-9. PubMed ID: 24715106
    [No Abstract]   [Full Text] [Related]  

  • 18. CTNNB1 gene mutations, pituitary transcription factors, and MicroRNA expression involvement in the pathogenesis of adamantinomatous craniopharyngiomas.
    Campanini ML; Colli LM; Paixao BM; Cabral TP; Amaral FC; Machado HR; Neder LS; Saggioro F; Moreira AC; Antonini SR; de Castro M
    Horm Cancer; 2010 Aug; 1(4):187-96. PubMed ID: 21761366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemistry or Molecular Analysis: Which Method Is Better for Subtyping Craniopharyngioma?
    Fukuhara N; Iwata T; Inoshita N; Yoshimoto K; Kitagawa M; Fukuhara H; Tatsushima K; Yamaguchi-Okada M; Takeshita A; Ito J; Takeuchi Y; Yamada S; Nishioka H
    Endocr Pathol; 2021 Jun; 32(2):262-268. PubMed ID: 32965631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy.
    Rostami E; Witt Nyström P; Libard S; Wikström J; Casar-Borota O; Gudjonsson O
    Acta Neurochir (Wien); 2017 Nov; 159(11):2217-2221. PubMed ID: 28918496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.